Development

Jazz faces uncertainty over Zepzelca's accelerated approval after Phase III LAGOON failure

Edited by Robert McTiernan··3 min read
Jazz faces uncertainty over Zepzelca's accelerated approval after Phase III LAGOON failure

The Phase III LAGOON trial has failed to confirm the second-line benefit of lurbinectedin (Zepzelca) in relapsed small cell lung cancer, a result that puts Jazz Pharmaceuticals plc (Nasdaq: JAZZ) under pressure to defend an accelerated approval that was always contingent on this outcome. The trial missed its primary endpoint of overall survival across all three arms, with lurbinectedin monotherapy producing a median OS of 8.7 months versus 10.7 months for the control arm — a hazard ratio of 1.190 that numerically favors the comparator. The combination arm of lurbinectedin plus irinotecan showed a median OS of 10.9 months, numerically similar to control, with an HR of 0.902.

Lurbinectedin is a selective inhibitor of oncogenic transcription that binds DNA and disrupts transcriptional processes on which small cell lung cancer cells are particularly dependent. The drug also modulates the tumor microenvironment by reducing tumor-associated macrophages and inflammatory signaling. These mechanisms contributed to the objective response rates observed in the Phase II study that supported the drug's accelerated approval in second-line SCLC in 2020.

Trial data

LAGOON is a Phase III, randomized, open-label, three-arm study enrolling 724 patients with SCLC who had progressed on prior platinum-based chemotherapy. Patients were randomized 1:1:1 to lurbinectedin 3.2 mg/m² monotherapy, lurbinectedin 2.0 mg/m² plus irinotecan 75 mg/m², or investigators' choice of topotecan or irinotecan.

A notable design feature was the inclusion of patients with a history of CNS involvement — a population excluded from the earlier Phase II study that supported accelerated approval. This broader enrollment appears to have materially affected the monotherapy result: patients with CNS metastases receiving lurbinectedin monotherapy had a median OS of 7.1 months versus 10.3 months for control (HR 1.791), while those without CNS involvement showed a median OS of 9.6 months versus 10.7 months for control (HR 1.106). The control arm also performed better than historical precedent, a pattern that can inflate hazard ratios against investigational arms. Tolerability data offered some distinction: Grade ≥3 treatment-related adverse events occurred in 35% of patients on lurbinectedin monotherapy versus 64.4% in the control arm, suggesting a cleaner safety profile even in the absence of a survival benefit.

The AllSci BriefSystematic R&D and deal news. Daily.

Competitive context

The failure places Jazz in a difficult regulatory position. The company has disclosed the results to the US FDA and will discuss next steps regarding post-marketing requirements for the second-line indication, which carries continued approval contingency. The accelerated approval granted in June 2020 was based on overall response rate and duration of response from a single-arm Phase II study — the very type of surrogate endpoint evidence that LAGOON was designed to verify.

Jazz has signaled its preferred path forward: consolidating lurbinectedin's commercial value in the first-line maintenance setting, where the Phase III IMforte trial demonstrated a statistically significant 27% reduction in the risk of death and a 46% reduction in the risk of progression or death when combined with Roche's Tecentriq (atezolizumab), leading to full FDA approval in October 2025. Cross-trial comparisons are limited, but the IMforte data represent a materially different risk-benefit profile than what LAGOON produced in the second-line setting. The second-line SCLC space remains contested: topotecan has long been the standard of care despite modest efficacy, and the LAGOON control arm's stronger-than-expected performance underscores how difficult it is to demonstrate incremental survival benefit in this population. The immediate regulatory question — whether the FDA will move to withdraw or modify the accelerated second-line approval — will define the commercial scope of Zepzelca outside its newly established first-line maintenance role.

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

Spot something wrong? Report an issue with this article